| Fantuzzo Oral, Maxillofacial, And Dental Implant Surgery, Pllc | |
|
77 Mahogany Run Pittsford NY 14534-9424 | |
| (585) 203-1524 | |
| Not Available |
| Full Name | Fantuzzo Oral, Maxillofacial, And Dental Implant Surgery, Pllc |
|---|---|
| Speciality | Dentist |
| Location | 77 Mahogany Run, Pittsford, New York |
| Authorized Official Name and Position | Joseph J Fantuzzo (OWNER/PROVIDER) |
| Authorized Official Contact | 5852031524 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Fantuzzo Oral, Maxillofacial, And Dental Implant Surgery, Pllc 1815 Clinton Ave. South Suite 320 Rochester NY 14618 Ph: () - | Fantuzzo Oral, Maxillofacial, And Dental Implant Surgery, Pllc 77 Mahogany Run Pittsford NY 14534-9424 Ph: (585) 203-1524 |
| NPI Number | 1275925380 |
|---|---|
| Provider Enumeration Date | 02/26/2015 |
| Last Update Date | 02/26/2015 |
| Medicare PECOS PAC ID | 4486957388 |
|---|---|
| Medicare Enrollment ID | O20160127001615 |
News Archive
Having a loved one go through a critical illness is a stressful and traumatic experience that may have lasting effects months after the patient is discharged from the intensive care unit.
U.S. Department of Health and Human Services Secretary Kathleen Sebelius wrote America's Health Insurance Plans (AHIP), the national association of health insurers, calling on their members to stop using scare tactics and misinformation to falsely blame premium increases for 2011 on the patient protections in the Affordable Care Act.
The Food and Drug Administration (FDA) has approved Merit Medical Systems, Inc.'s phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere™ Microspheres (hqTACE) for delivery of doxorubicin. The clinical trial will involve U.S. and international interventional radiologists who treat patients with localized, unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer.
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the European Commission has granted a marketing authorization for the oral receptor tyrosine kinase inhibitor LENVIMA (lenvatinib mesylate) as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.
Ameritox, the leader in pain-medication monitoring, today announced the launch of Rx Guardian CD, its next-generation pain-medication monitoring solution and part of the patented Rx Guardian process.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275925380 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223S0112X | Dentist - Oral And Maxillofacial Surgery | 048604 (New York) | Primary |
| Provider Name | Joseph J Fantuzzo |
|---|---|
| Provider Type | Practitioner - Maxillofacial Surgery |
| Provider Identifiers | NPI Number: 1073620373 PECOS PAC ID: 8729033949 Enrollment ID: I20050321000367 |
News Archive
Having a loved one go through a critical illness is a stressful and traumatic experience that may have lasting effects months after the patient is discharged from the intensive care unit.
U.S. Department of Health and Human Services Secretary Kathleen Sebelius wrote America's Health Insurance Plans (AHIP), the national association of health insurers, calling on their members to stop using scare tactics and misinformation to falsely blame premium increases for 2011 on the patient protections in the Affordable Care Act.
The Food and Drug Administration (FDA) has approved Merit Medical Systems, Inc.'s phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere™ Microspheres (hqTACE) for delivery of doxorubicin. The clinical trial will involve U.S. and international interventional radiologists who treat patients with localized, unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer.
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the European Commission has granted a marketing authorization for the oral receptor tyrosine kinase inhibitor LENVIMA (lenvatinib mesylate) as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.
Ameritox, the leader in pain-medication monitoring, today announced the launch of Rx Guardian CD, its next-generation pain-medication monitoring solution and part of the patented Rx Guardian process.
› Verified 3 days ago
News Archive
Having a loved one go through a critical illness is a stressful and traumatic experience that may have lasting effects months after the patient is discharged from the intensive care unit.
U.S. Department of Health and Human Services Secretary Kathleen Sebelius wrote America's Health Insurance Plans (AHIP), the national association of health insurers, calling on their members to stop using scare tactics and misinformation to falsely blame premium increases for 2011 on the patient protections in the Affordable Care Act.
The Food and Drug Administration (FDA) has approved Merit Medical Systems, Inc.'s phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere™ Microspheres (hqTACE) for delivery of doxorubicin. The clinical trial will involve U.S. and international interventional radiologists who treat patients with localized, unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer.
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the European Commission has granted a marketing authorization for the oral receptor tyrosine kinase inhibitor LENVIMA (lenvatinib mesylate) as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.
Ameritox, the leader in pain-medication monitoring, today announced the launch of Rx Guardian CD, its next-generation pain-medication monitoring solution and part of the patented Rx Guardian process.
› Verified 3 days ago
Canalside Dentistry Pllc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 69a Monroe Ave, Pittsford, NY 14534 Phone: 585-586-2580 Fax: 585-586-4924 | |
Harpreet Deol Dds Llc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 151 Sullys Trl Ste 2, Pittsford, NY 14534 Phone: 585-248-3672 | |
Progressive Dental Specialists Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 151 Sullys Trl, Progressive Implantology & Periodontics, Pittsford, NY 14534 Phone: 585-385-4867 Fax: 585-385-4914 | |
Hanson Dental Practice, Pllc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 600 Kreag Rd, Pittsford, NY 14534 Phone: 585-248-2494 | |
Finger Lakes Periodontics Pllc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 600 Kreag Rd, Pittsford, NY 14534 Phone: 585-248-8195 Fax: 585-248-8256 | |
Jan M. Piper-glasgow, Dmd Pc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 40 Grove St # B, Pittsford, NY 14534 Phone: 585-586-3990 Fax: 585-586-4389 |